{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:42:16Z","timestamp":1791466936601,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13010-1","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:18:57Z","timestamp":1728382737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum cyfra21-1 is a new prognostic biomarker of penile squamous cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Haitao","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taonong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zike","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"Suppl 6","key":"13010_CR1","doi-asserted-by":"publisher","first-page":"i115","DOI":"10.1093\/annonc\/mdt286","volume":"24","author":"H Van Poppel","year":"2013","unstructured":"Van Poppel H, Watkin NA, Osantoet S. Penile cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):i115\u201324.","journal-title":"Ann Oncol"},{"issue":"6","key":"13010_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.eururo.2010.01.039","volume":"57","author":"G Pizzocaro","year":"2010","unstructured":"Pizzocaro G, Algaba F. Horenblaset al. EAU penile cancer guidelines 2009. Eur Urol. 2010;57(6):1002\u201312.","journal-title":"Eur Urol"},{"issue":"12","key":"13010_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Brayet F. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893\u2013917.","journal-title":"Int J Cancer"},{"issue":"3","key":"13010_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ucl.2010.04.003","volume":"37","author":"PL Crispen","year":"2010","unstructured":"Crispen PL, Mydlo JH. Penile intraepithelial neoplasia and other premalignant lesions of the penis. Urol Clin North Am. 2010;37(3):335\u201342.","journal-title":"Urol Clin North Am"},{"issue":"5","key":"13010_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.urolonc.2006.08.029","volume":"25","author":"JS Barnholtz-Sloan","year":"2007","unstructured":"Barnholtz-Sloan JS, Maldonado JL. Pow-sanget al. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007;25(5):361\u20137.","journal-title":"Urol Oncol"},{"issue":"1","key":"13010_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","volume":"7","author":"A Thomas","year":"2021","unstructured":"Thomas A, Necchi A. Muneeret al. Penile cancer. Nat Rev Dis Primers. 2021;7(1):11.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"13010_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","volume":"67","author":"OW Hakenberg","year":"2015","unstructured":"Hakenberg OW, Comperat EM, Minhaset S. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142\u201350.","journal-title":"Eur Urol"},{"issue":"12","key":"13010_CR8","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1038\/bjc.2015.457","volume":"113","author":"ZS Li","year":"2015","unstructured":"Li ZS, Yao K, Chenet P. Modification of N staging systems for penile cancer: a more precise prediction of prognosis. Br J Cancer. 2015;113(12):1746.","journal-title":"Br J Cancer"},{"issue":"5","key":"13010_CR9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.juro.2008.07.040","volume":"180","author":"Y Zhu","year":"2008","unstructured":"Zhu Y, Ye DW, Yaoet XD. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol. 2008;180(5):2019\u201323.","journal-title":"J Urol"},{"issue":"3","key":"13010_CR10","first-page":"396","volume":"33","author":"Y Takahashi","year":"1987","unstructured":"Takahashi Y, Horie M. Isogaiet al. [Clinical study of serum squamous cell carcinoma-related antigen levels in penile cancer]. Hinyokika Kiyo. 1987;33(3):396\u20139.","journal-title":"Hinyokika Kiyo"},{"issue":"5","key":"13010_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1590\/s1677-5538.ibju.2020.0959","volume":"47","author":"DS Zekan","year":"2021","unstructured":"Zekan DS, Dahman A, Hajiranet AJ. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol. 2021;47(5):943\u201356.","journal-title":"Int Braz J Urol"},{"key":"13010_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1471-2407-13-223","volume":"13","author":"S Steffens","year":"2013","unstructured":"Steffens S, Al GA, Steinestelet J. High CRP values predict poor survival in patients with penile cancer. BMC Cancer. 2013;13:223.","journal-title":"BMC Cancer"},{"key":"13010_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2490-13-53","volume":"13","author":"A Ghazal","year":"2013","unstructured":"Ghazal A, Al S, Steffens J, Steinestelet. Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer. BMC Urol. 2013;13:53.","journal-title":"BMC Urol"},{"issue":"2","key":"13010_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/172460089400900204","volume":"9","author":"P Stieber","year":"1994","unstructured":"Stieber P, Dienemann H, Hasholzneret U. Comparison of CYFRA 21\u2009\u2013\u20091, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers. 1994;9(2):82\u20138.","journal-title":"Int J Biol Markers"},{"key":"13010_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2017.12.020","volume":"194","author":"ZF Jiang","year":"2018","unstructured":"Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci. 2018;194:1\u20136.","journal-title":"Life Sci"},{"issue":"11","key":"13010_CR16","first-page":"3221","volume":"48","author":"JL Broers","year":"1988","unstructured":"Broers JL, Ramaekers FC, Rotet MK. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988;48(11):3221\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"13010_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/JTO.0b013e31824a8db0","volume":"7","author":"MJ Edelman","year":"2012","unstructured":"Edelman MJ, Hodgson L, Rosenblattet PY. CYFRA 21\u2009\u2013\u20091 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012;7(4):649\u201354.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"13010_CR18","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.7314\/APJCP.2014.15.22.9611","volume":"15","author":"B Wang","year":"2014","unstructured":"Wang B, He YJ, Tianet YX. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac J Cancer Prev. 2014;15(22):9611\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"13010_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1378\/chest.109.1.104","volume":"109","author":"L Trevisani","year":"1996","unstructured":"Trevisani L, Putinati S, Sartoriet S. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Chest. 1996;109(1):104\u20138.","journal-title":"Chest"},{"issue":"3","key":"13010_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/1724600819868234","volume":"34","author":"L Fu","year":"2019","unstructured":"Fu L, Wang R, Yinet L. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis. Int J Biol Markers. 2019;34(3):251\u201361.","journal-title":"Int J Biol Markers"},{"key":"13010_CR21","doi-asserted-by":"crossref","unstructured":"Ju M, Di Ge X X Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma. Front Oncol et al. 2021, 11: 789312.","DOI":"10.3389\/fonc.2021.789312"},{"issue":"4","key":"13010_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2217\/bmm.13.55","volume":"7","author":"L Liu","year":"2013","unstructured":"Liu L, Liu B, Zhuet LL. CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma. Biomark Med. 2013;7(4):591\u20139.","journal-title":"Biomark Med"},{"issue":"1","key":"13010_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/dote\/11.1.35","volume":"11","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Ide H, Eguchiet R. CYFRA 21\u2009\u2013\u20091 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus. 2017;11(1):35\u20139.","journal-title":"Dis Esophagus"},{"issue":"1","key":"13010_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s13277-015-3914-0","volume":"37","author":"B Kotowicz","year":"2016","unstructured":"Kotowicz B, Fuksiewicz M, Jonska-Gmyreket J. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 2016;37(1):1271\u20138.","journal-title":"Tumour Biol"},{"issue":"3","key":"13010_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0959-8049(97)89010-7","volume":"33","author":"JM Brechot","year":"1997","unstructured":"Brechot JM, Chevret S, Natafet J. Diagnostic and prognostic value of Cyfra 21\u2009\u2013\u20091 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33(3):385\u201391.","journal-title":"Eur J Cancer"},{"issue":"1","key":"13010_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s004080000047","volume":"179","author":"D Karnak","year":"2001","unstructured":"Karnak D, Ulubay G, Kayacanet O. Evaluation of Cyfra 21\u2009\u2013\u20091: a potential tumor marker for non-small cell lung carcinomas. Lung. 2001;179(1):57\u201365.","journal-title":"Lung"},{"issue":"1\u20132","key":"13010_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20452\/pamw.598","volume":"119","author":"M Kosacka","year":"2009","unstructured":"Kosacka M, Jankowska R. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21\u2009\u2013\u20091 levels in non-small cell lung cancer. Pol Arch Med Wewn. 2009;119(1\u20132):33\u20137.","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"13010_CR28","first-page":"35","volume":"59","author":"S Hanada","year":"2013","unstructured":"Hanada S, Nishiyama N, Mizuguchiet S. Clinicopathological significance of combined analysis of cytokeratin19 expression and preoperative serum CYFRA21-1 levels in human lung squamous cell carcinoma. Osaka City Med J. 2013;59(1):35\u201344.","journal-title":"Osaka City Med J"},{"key":"13010_CR29","doi-asserted-by":"crossref","unstructured":"Pinkheaw N, Sathitruangsak C, Tanthanuchet M. al. Real world data of recurrent and survival rates of penile cancer patients in Songklanagarind hospital: Tumor stage as a predictor for disease-free survival. Int J Urol. 2024;31(2):144-153.","DOI":"10.1111\/iju.15326"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T02:03:14Z","timestamp":1728439394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13010"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13010-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For its retrospective limitation, writing informed consent from the patients was not available, ethics approval from the Sun Yat-sen University Cancer Center Institute Research Ethics Committee (approval number: B2023-618-01 ) was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consents were obtained from the patients or legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1240"}}